FDA to Review MPI-2505 NDA for RA, Psoriasis Medac Pharma announced that the FDA has approved Rasuvo (methotrexate) subcutaneous auto-injector for the management of rheumatoid arthritis, polyarticular ...
The US Food and Drug Administration (FDA) has approved a subcutaneous injectable methotrexate delivered in an auto-injector (Rasuvo, Medac Pharma) for rheumatoid arthritis (RA), polyarticular-course ...
FDA to Review MPI-2505 NDA for RA, Psoriasis Medac Pharma announced the launch of Rasuvo (methotrexate) injection for patients with rheumatoid arthritis, polyarticular course juvenile idiopathic ...
Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug ...
Medac Pharma hired HCB Health as AOR for Rasuvo, an injectable drug used to treat patients with rheumatoid arthritis and psoriasis. The firm is tasked with developing professional digital media and ...
If you’re looking at treatment options for psoriasis, arthritis, or certain kinds of cancer, you may want to learn more about methotrexate. For more details on methotrexate’s uses and more, see this ...